| Blue toe syndrome and sunitinib. | |
| | |
MedLine Citation:
|
PMID: 21136131 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We present a patient with metastatic renal cell carcinoma treated with sunitinib, a multitargeted tyrosine kinase inhibitor. The patient experienced bilateral blue toe syndrome which we related to sunitinib use. Discontinuation of sunitinib to lower the patient's prothrombotic state and increase the ability to form collaterals, together with the addition of low-molecular-weight heparin to treat the occluding thrombi, resulted in waning of the blue toe syndrome. This case adds to the accumulating evidence of possible untoward cardiovascular side effects that should be taken into consideration in patients on tyrosine kinase inhibitors such as sunitinib. |
| | |
Authors:
|
Pieter G Postema; Madelien V Regeer; Paul R van der Valk; Erik S G Stroes; Dick J Richel |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2010-12-08 |
Journal Detail:
|
Title: International journal of clinical oncology Volume: 16 ISSN: 1437-7772 ISO Abbreviation: Int. J. Clin. Oncol. Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-10-13 Completed Date: 2012-02-13 Revised Date: 2012-12-13 |
Medline Journal Info:
|
Nlm Unique ID: 9616295 Medline TA: Int J Clin Oncol Country: Japan |
Other Details:
|
Languages: eng Pagination: 574-6 Citation Subset: IM |
Affiliation:
|
Department of Oncology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
adverse effects*,
therapeutic use Blue Toe Syndrome / chemically induced*, pathology Carcinoma, Renal Cell / drug therapy*, pathology Heparin, Low-Molecular-Weight / therapeutic use Humans Indoles / adverse effects*, therapeutic use Kidney Neoplasms / drug therapy*, pathology Male Middle Aged Neoplasm Metastasis Protein Kinase Inhibitors / adverse effects, therapeutic use Pyrroles / adverse effects*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Heparin, Low-Molecular-Weight; 0/Indoles; 0/Protein Kinase Inhibitors; 0/Pyrroles; 0/sunitinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intraindividual comparison of gadolinium- and iodine-enhanced 64-slice multidetector CT pulmonary an...
Next Document: A survey of disclosure of diagnosis to patients with glioma in Japan.